Understanding Darzalex

Darzalex® (daratumumab) is a laboratory-made monoclonal antibody that targets a specific single protein on the surface of myeloma cells. Of the four new therapies for myeloma approved in 2015 by the FDA, only Darzalex has single-agent activity and was approved with “breakthrough” status.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt out, click for more information.